Continuous innovation crucial to improve healthcare across Europe, says trade group

The 2nd Value Added Medicines conference, which took place in Brussels, Belgium, yesterday, gathered a wide range of experts in the healthcare community to raise awareness, informed debate with the mutual intention to present solutions for maximizing the benefits of and encouraging the development of continuous innovation.

A concluding statement cited the examples of adjustments on purchasing/procurement processes, acceptance of adequate evidence and, where needed, adjustment of pricing and reimbursement barriers, as well as seizing the benefits of digital technologies and increased stakeholder collaboration should be maximized to bring value added medicines to patients.

Marc-Alexander Mahl, president of Medicines for Europe, which represents generic and biosimilar drugmakers, at the meeting highlighted that “today’s event brought stakeholders who care about patient access to medicines together to reflect on the role of continuous innovation to deliver efficient and sustainable solutions to patient needs.”